XML 42 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Segments of Business and Geographic Areas
 6 Months Ended
Jul. 02, 2023
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS
SALES BY SEGMENT OF BUSINESS
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)July 2,
2023		July 3,
2022		Percent
Change		July 2,
2023		July 3,
2022		Percent Change
CONSUMER HEALTH   
OTC
     U.S.$712 663 7.5 %$1,457 1,333 9.3 %
     International947 818 15.7 1,844 1,609 14.6 
     Worldwide 1,659 1,482 12.0 3,301 2,943 12.2 
Skin Health/Beauty
     U.S.650 629 3.4 1,267 1,173 8.0 
     International498 497 0.3 991 965 2.7 
     Worldwide 1,148 1,126 2.0 2,258 2,138 5.6 
Oral Care
     U.S.173 170 1.7 332 313 6.2 
     International225 224 0.3 427 447 (4.7)
     Worldwide 398 394 0.9 759 760 (0.2)
Baby Care
     U.S.99 88 12.5 195 173 12.7 
     International261 287 (9.1)524 557 (6.0)
     Worldwide 360 375 (4.0)719 730 (1.6)
Women’s Health
     U.S.4 3 (2.1)7 7 (0.1)
     International235 228 3.5 449 452 (0.7)
     Worldwide 238 230 3.4 455 458 (0.6)
Wound Care/Other
     U.S.149 133 12.3 264 245 7.9 
     International58 65 (10.3)107 117 (8.4)
     Worldwide 207 197 4.9 371 361 2.6 
TOTAL CONSUMER HEALTH
     U.S.1,787 1,687 6.0 3,522 3,244 8.6 
     International2,224 2,118 5.0 4,341 4,147 4.7 
     Worldwide 4,011 3,805 5.4 7,863 7,391 6.4 
PHARMACEUTICAL
Immunology
     U.S.2,865 2,853 0.4 5,313 5,354 (0.8)
     International1,631 1,559 4.7 3,295 3,176 3.8 
     Worldwide 4,496 4,411 1.9 8,608 8,530 0.9 
     REMICADE
     U.S.277 391 (29.3)553 749 (26.2)
     U.S. Exports33 44 (24.9)74 124 (40.3)
     International152 212 (28.2)322 437 (26.2)
     Worldwide 462 647 (28.6)949 1,310 (27.5)
     SIMPONI / SIMPONI ARIA
     U.S.285 301 (5.1)556 588 (5.4)
     International244 266 (8.2)510 549 (7.1)
     Worldwide 529 566 (6.6)1,066 1,137 (6.2)
     STELARA
     U.S.1,817 1,731 4.9 3,268 3,110 5.1 
     International981 868 13.0 1,974 1,777 11.1 
     Worldwide 2,797 2,599 7.6 5,241 4,887 7.2 
     TREMFYA
     U.S.450 382 17.8 856 773 10.7 
     International255 214 19.4 489 413 18.4 
     Worldwide 706 597 18.3 1,346 1,187 13.4 
     OTHER IMMUNOLOGY
     U.S.4 3 17.8 7 9 (30.2)
     International00— 00—
     Worldwide 4 3 17.8 7 9 (30.2)
Infectious Diseases
     U.S.395 415 (4.9)787 876 (10.2)
     International727 901 (19.4)1,920 1,737 10.5 
     Worldwide 1,121 1,316 (14.8)2,707 2,613 3.6 
     COVID-19 VACCINE
     U.S.— 45 *— 120 *
     International285 499 (43.0)1,032 881 17.1
     Worldwide285 544 (47.7)1,032 1,001 3.0
     EDURANT / rilpivirine
     U.S.8 9 (9.0)17 18 (5.3)
     International258 215 19.9 529 454 16.4 
     Worldwide 266 225 18.6 546 473 15.6 
      PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     U.S.382 355 7.6 760 724 5.0 
     International109 110 (0.2)208 242 (13.9)
     Worldwide 491 464 5.8 968 965 0.3 
     OTHER INFECTIOUS DISEASES
     U.S.5 6 (27.2)10 14 (30.6)
     International74 77 (3.5)151 160 (5.6)
     Worldwide 79 83 (5.2)161 174 (7.6)
Neuroscience
     U.S.1,029 896 14.9 2,007 1,739 15.4 
     International764 837 (8.8)1,590 1,735 (8.4)
     Worldwide 1,793 1,734 3.5 3,597 3,475 3.5 
     CONCERTA / methylphenidate
     U.S.64 38 68.2 134 73 84.0 
     International143 123 16.3 279 245 13.9 
     Worldwide 208 161 28.6 414 318 30.0 
     INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
     U.S.721 691 4.3 1,434 1,352 6.0 
     International310 362 (14.4)641 749 (14.5)
     Worldwide 1,031 1,054 (2.1)2,075 2,102 (1.3)
     SPRAVATO
     U.S.144 74 93.2 255 135 88.3 
     International25 11 *45 20 *
     Worldwide 169 85 98.2 300 155 93.1 
     OTHER NEUROSCIENCE(1)
     U.S.100 93 9.3 184 179 3.1 
     International286 341 (16.4)625 721 (13.4)
     Worldwide 386 433 (10.9)809 900 (10.1)
Oncology
     U.S.2,069 1,679 23.2 3,958 3,261 21.4 
     International2,329 2,362 (1.4)4,552 4,731 (3.8)
     Worldwide 4,398 4,042 8.8 8,510 7,992 6.5 
      CARVYKTI
     U.S.114 24 *184 24 *
     International3 — *5 — *
     Worldwide117 24 *189 24 *
     DARZALEX
     U.S.1,322 1,021 29.5 2,513 1,974 27.3 
     International1,110 965 15.0 2,182 1,868 16.8 
     Worldwide 2,431 1,986 22.4 4,695 3,842 22.2 
     ERLEADA
     U.S.241 233 3.6 49043911.8 
     International326 218 49.7 61941250.3 
     Worldwide 567 450 25.9 1,109 85030.4 
     IMBRUVICA
     U.S.262 349 (24.9)532 719 (26.0)
     International579 620 (6.7)1,136 1,288 (11.8)
     Worldwide 841 970 (13.2)1,668 2,008 (16.9)
     ZYTIGA / abiraterone acetate
     U.S.9 19 (55.2)25 38 (34.7)
     International218 486 (55.1)447 1,006 (55.6)
     Worldwide 227 505 (55.1)472 1,044 (54.8)
     OTHER ONCOLOGY
     U.S.122 33 *214 67 *
     International92 72 27.8 162 156 3.6 
     Worldwide 214 106 *376 224 68.0 
Pulmonary Hypertension
     U.S.684 560 22.0 1,284 1,132 13.4 
     International289 284 2.0 561 563 (0.4)
     Worldwide 972 843 15.3 1,844 1,695 8.8 
     OPSUMIT
     U.S.328 265 23.7 601 538 11.6 
     International179 173 3.4 346 343 0.9 
     Worldwide 507 438 15.7 947 881 7.5 
     UPTRAVI
     U.S.338 272 24.2 642 541 18.7 
     International61 56 10.0 119 112 6.6 
     Worldwide 399 328 21.8 761 653 16.6 
     OTHER PULMONARY HYPERTENSION
     U.S.18 23 (23.8)41 53 (23.0)
     International48 55 (10.9)95 108 (11.7)
     Worldwide 66 78 (14.7)136 161 (15.5)
Cardiovascular / Metabolism / Other
     U.S.776 757 2.6 1,491 1,429 4.3 
     International174 215 (19.0)386 453 (14.7)
     Worldwide 950 972 (2.2)1,877 1,882 (0.3)
     XARELTO
     U.S.637 609 4.7 1,215 1,117 8.8 
     International— — — — — — 
     Worldwide 637 609 4.7 1,215 1,117 8.8 
     OTHER(2)
     U.S.138 148 (6.3)275 312 (11.8)
     International174 215 (19.0)386 453 (14.7)
     Worldwide 313 363 (13.8)662 765 (13.5)
TOTAL PHARMACEUTICAL  
     U.S.7,818 7,159 9.2 14,841 13,791 7.6 
     International5,913 6,158 (4.0)12,303 12,395 (0.7)
     Worldwide 13,731 13,317 3.1 27,144 26,186 3.7 
MEDTECH
Interventional Solutions
     U.S.908 525 73.1 1,771 1,019 73.8 
     International712 525 35.7 1,352 1,123 20.5 
     Worldwide 1,620 1,049 54.4 3,123 2,141 45.8 
     ELECTROPHYSIOLOGY
     U.S.609 499 22.0 1,180 969 21.7 
     International587 469 25.1 1,109 1,001 10.8 
     Worldwide1,196 968 23.5 2,288 1,970 16.2 
     ABIOMED(3)
     U.S.272 — *536 — *
     International59 — *119 — *
     Worldwide331 — *655 — *
     OTHER INTERVENTIONAL SOLUTIONS
     U.S.27 26 4.5 55 51 10.8 
     International67 56 20.0 125 121 2.8 
     Worldwide93 81 15.1 180 171 5.1 
Orthopaedics
     U.S.1,388 1,338 3.7 2,751 2,627 4.7 
     International878 820 7.0 1,759 1,719 2.3 
     Worldwide 2,265 2,157 5.0 4,510 4,345 3.8 
     HIPS
     U.S.250 240 4.1 491 465 5.6 
     International147 148 (0.8)296 312 (5.1)
     Worldwide 397 388 2.2 787 777 1.3 
     KNEES
     U.S.221 216 2.4 447 417 7.2 
     International142 133 6.3 284 271 4.8 
     Worldwide 363 349 3.9 731 688 6.3 
     TRAUMA
     U.S.483 464 4.3 974 939 3.7 
     International255 232 9.9 522 505 3.2 
     Worldwide 739 696 6.1 1,496 1,444 3.6 
     SPINE, SPORTS & OTHER
     U.S.433 418 3.5 839 805 4.1 
     International334 306 9.0 657 630 4.2 
     Worldwide 766 724 5.8 1,495 1,436 4.2 
Surgery
     U.S.1,015 992 2.2 1,990 1,913 4.0 
     International1,580 1,458 8.4 3,039 2,971 2.3 
     Worldwide 2,594 2,450 5.9 5,028 4,884 3.0 
     ADVANCED
     U.S.466 454 2.7 910 871 4.5 
     International757 702 7.8 1,430 1,431 0.0
     Worldwide 1,222 1,156 5.8 2,340 2,302 1.7 
     GENERAL
     U.S.548 538 1.9 1,079 1,042 3.6 
     International823 756 8.9 1,608 1,540 4.5 
     Worldwide 1,372 1,294 6.0 2,688 2,582 4.1 
Vision
     U.S.529 496 6.6 1,087 1,017 6.9 
     International778 745 4.6 1,521 1,481 2.7 
     Worldwide 1,308 1,241 5.4 2,608 2,498 4.4 
     CONTACT LENSES / OTHER
     U.S.409 374 9.1 853 774 10.1 
     International530 519 2.2 1,039 1,030 0.9 
     Worldwide 939 894 5.1 1,892 1,804 4.9 
     SURGICAL
     U.S.120 122 (1.1)234 243 (3.6)
     International249 225 10.1 482 451 6.7 
     Worldwide 369 347 6.2 716 694 3.1 
TOTAL MEDTECH    
     U.S.3,839 3,351 14.6 7,598 6,576 15.5 
     International3,949 3,547 11.3 7,671 7,293 5.2 
     Worldwide 7,788 6,898 12.9 15,269 13,869 10.1 
WORLDWIDE      
     U.S.13,444 12,197 10.2 25,961 23,611 10.0 
     International12,086 11,823 2.2 24,315 23,835 2.0 
     Worldwide $25,530 24,020 6.3 %$50,276 47,446 6.0 %
*Percentage greater than 100% or not meaningful
(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately
(2) Inclusive of INVOKANA which was previously disclosed separately
(3) Acquired on December 22, 2022

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)July 2,
2023		July 3,
2022		Percent
Change		July 2,
2023		July 3,
2022		Percent
Change
Consumer Health(1)
$860 784 9.7 %$1,636 1,470 11.3%
Pharmaceutical(2)
4,862 4,420 10.0 9,306 8,344 11.5 
MedTech(3)
1,699 1,141 48.93,144 2,618 20.1 
Segment earnings before provision for taxes7,421 6,345 17.0 14,086 12,432 13.3 
Less: Expense not allocated to segments (4)
377 237  7,479 360 
Less: Consumer Health separation costs 282 268 582 370 
Worldwide income before tax$6,762 5,840 15.8%$6,025 11,702 (48.5)%
*Percentage greater than 100% or not meaningful
(1) Consumer Health includes:
•Intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2023 and 2022.
Intangible amortization expense of $0.2 billion in both the fiscal six months of 2023 and 2022.

(2) Pharmaceutical includes:
•Intangible amortization expense of $0.7 billion in both the fiscal second quarter of 2023 and 2022.
Intangible amortization expense of $1.5 billion in both the fiscal six months of 2023 and 2022.
•One-time COVID-19 Vaccine related exit costs of $0.2 billion and $0.3 billion in the fiscal second quarter of 2023 and 2022, respectively. One-time COVID-19 Vaccine related exit costs of $0.6 billion and $0.3 billion in the fiscal six months of 2023 and 2022, respectively.
•A restructuring related charge of $0.1 billion and $0.3 billion in the fiscal second quarter and fiscal six months of 2023, respectively.
•In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).
•Unfavorable changes in the fair value of securities of $0.1 billion in the fiscal second quarter of 2022. Unfavorable changes in the fair value of securities of $0.1 billion and $0.5 billion in the fiscal six months of 2023 and 2022, respectively.
•Favorable litigation related items of $0.1 billion in both the fiscal second quarter and fiscal six months of 2023.

(3) MedTech includes:
•Intangible amortization expense of $0.4 billion and $0.3 billion in the fiscal second quarter of 2023 and 2022, respectively. Intangible amortization expense of $0.8 billion and $0.5 billion in the fiscal six months of 2023 and 2022, respectively.
•Net favorable litigation matters of $0.2 billion in both the fiscal second quarter and fiscal six months of 2023 and $0.3 billion of expense in both the fiscal second quarter and fiscal six months of 2022.
•Acquisition and integration related expense of $0.1 billion in the fiscal six months of 2023.
•A restructuring related charge of $0.1 billion in the fiscal second quarter of 2022 and $0.2 billion in the fiscal six months of 2022.

(4)Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal six months of 2023 includes an approximately $7 billion incremental charge primarily related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details.

SALES BY GEOGRAPHIC AREA
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)July 2, 2023July 3, 2022Percent
Change		July 2, 2023July 3, 2022Percent Change
United States$13,444 12,197 10.2 %$25,961 23,611 10.0 %
Europe5,894 6,085 (3.1)12,226 12,109 1.0 
Western Hemisphere, excluding U.S.1,713 1,536 11.5 3,300 3,018 9.3 
Asia-Pacific, Africa4,479 4,202 6.6 8,789 8,708 0.9 
Total$25,530 24,020 6.3 %$50,276 47,446 6.0 %